This Plain Language Summary of publication article (PLSP) from Future Neurology explains a clinical study of low-sodium oxybate (LXB) for adults with idiopathic hypersomnia, a sleep disorder causing severe daytime drowsiness and prolonged sleep. The study assessed symptom changes after 12 to 16 weeks of LXB treatment, followed by either a 2-week placebo or continued LXB use. The study assessed changes in symptoms and their effects on daily functioning and quality of life.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study’ that was published in The Lancet Neurology.

Visit The Lancet using the link to read the original article